BeEAM (bendamustine, etoposide, cytarabine, melphalan) versus BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning regimen before autologous …
R Wu, L Ma - Cell Transplantation, 2023 - journals.sagepub.com
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a
standard of care for selected patients with refractory/relapsed Hodgkin's lymphoma (HL) or …
standard of care for selected patients with refractory/relapsed Hodgkin's lymphoma (HL) or …
A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience
K Saleh, A Danu, S Koscielny, C Legoupil… - Leukemia & …, 2018 - Taylor & Francis
The combination of carmustine, etoposide, aracytin, and melphalan (BEAM) conditioning
regimen in autologous stem-cell transplantation (ASCT) is widely used in patients with …
regimen in autologous stem-cell transplantation (ASCT) is widely used in patients with …
Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning …
A Frankiewicz, M Saduś-Wojciechowska… - Contemporary …, 2018 - termedia.pl
Results Median time to neutrophil> 0.5× 109/l recovery was 10 days in both groups (p=
0.29), while median time to platelet> 50× 109/l recovery was 13 and 14 days after BEAM and …
0.29), while median time to platelet> 50× 109/l recovery was 13 and 14 days after BEAM and …
BEAM or BeEAM high-dose chemotherapy followed by ASCT: A single center comparative analysis of toxicity
V Ribrag, K Saleh, A Danu, S Koscielny, S Pilorge… - 2016 - ashpublications.org
Abstract Introduction: The BEAM (carmustine (BCNU), etoposide, aracytin and melphalan)
standard conditioning regimen in autologous stem-cell transplantation is widely used since …
standard conditioning regimen in autologous stem-cell transplantation is widely used since …
BEAC (carmustine, etoposide, cytarabine, and cyclophosphamide) in autologous hematopoietic cell transplantation: a safe and effective alternative conditioning …
I Sakellari, E Gavriilaki, S Bouziana… - Bone marrow …, 2019 - nature.com
We read with great interest the recently published report of the EBMT-Lymphoma Working
Party focusing on BEAC conditioning for non-Hodgkin lymphoma (NHL)[1]. Optimal …
Party focusing on BEAC conditioning for non-Hodgkin lymphoma (NHL)[1]. Optimal …
Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as …
MA Eltelbanei, NA El-Bassiouny, MS Abdalla, M Khalaf… - BMC cancer, 2024 - Springer
Autologous stem cell transplantation (ASCT) is a pivotal treatment for lymphoma patients.
The BeEAM regimen (Bendamustine, Etoposide, Cytarabine, Melphalan) traditionally relies …
The BeEAM regimen (Bendamustine, Etoposide, Cytarabine, Melphalan) traditionally relies …
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients
G Visani, L Malerba, PM Stefani… - Blood, The Journal …, 2011 - ashpublications.org
We designed a phase 1-2 study to evaluate the safety and the efficacy of increasing doses of
bendamustine (160 mg/m2, 180 mg/m2, and 200 mg/m2 given on days− 7 and− 6) coupled …
bendamustine (160 mg/m2, 180 mg/m2, and 200 mg/m2 given on days− 7 and− 6) coupled …
High‐dose Bendamustine‐EAM followed by autologous stem cell rescue results in long‐term remission rates in lymphoma patients, without renal toxicity
T Noesslinger, M Panny, R Simanek… - European journal of …, 2018 - Wiley Online Library
Background Autologous stem cell transplantation (ASCT) following BEAM (BCNU,
etoposide, cytarabine, melphalan) conditioning is standard of care in relapsed low‐and high …
etoposide, cytarabine, melphalan) conditioning is standard of care in relapsed low‐and high …
BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy
In many stem cell transplant centres, BCNU, etoposide, cytarabine and melphalan (BEAM)
high-dose chemotherapy (HDCT) has been replaced by the more economic and available …
high-dose chemotherapy (HDCT) has been replaced by the more economic and available …
BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre, randomised, phase 2 trial
F Keil, AMS Müller, A Berghold, R Riedl… - …, 2023 - thelancet.com
Background Replacement of carmustine (BCNU) in the BEAM regimen (BCNU, etoposide,
cytarabine, melphalan) with bendamustine (BendaEAM) before autologous stem cell …
cytarabine, melphalan) with bendamustine (BendaEAM) before autologous stem cell …